Literature DB >> 24333092

Key issues in inhibitor management in patients with haemophilia.

Keith Gomez1, Robert Klamroth2, Johnny Mahlangu3, Maria E Mancuso4, María E Mingot5, Margareth Castro Ozelo6.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24333092      PMCID： PMC3934290          DOI： 10.2450/2013.0246-12

Source DB:  PubMed          Journal:  Blood Transfus        ISSN： 1723-2007            Impact factor:   3.443


× No keyword cloud information.
  79 in total

1.  The use of factor VIII/von Willebrand factor concentrate for immune tolerance induction in haemophilia A patients with high-titre inhibitors: association of clinical outcome with inhibitor epitope profile.

Authors:  D A Greninger; J M Saint-Remy; M Jacquemin; A Benhida; D M DiMichele
Journal:  Haemophilia       Date:  2007-12-12       Impact factor: 4.287

2.  Prophylactic versus on-demand treatment strategies for severe haemophilia: a comparison of costs and long-term outcome.

Authors:  K Fischer; J G van der Bom; P Molho; C Negrier; E P Mauser-Bunschoten; G Roosendaal; P De Kleijn; D E Grobbee; H M van den Berg
Journal:  Haemophilia       Date:  2002-11       Impact factor: 4.287

3.  Current European practice in immune tolerance induction therapy in patients with haemophilia and inhibitors.

Authors:  J Astermark; M Morado; A Rocino; H M van den Berg; M von Depka; A Gringeri; L Mantovani; R P Garrido; M Schiavoni; A Villar; J Windyga
Journal:  Haemophilia       Date:  2006-07       Impact factor: 4.287

4.  A consensus statement on clinical trials of bypassing agent prophylaxis in inhibitor patients.

Authors:  J Teitel; E Berntorp; G Dolan; K Fischer; A Gringeri; C Kessler; T Lambert; C Leissinger; L Nemes; M Shima
Journal:  Haemophilia       Date:  2011-03-03       Impact factor: 4.287

5.  Dosing and effectiveness of recombinant activated factor VII (rFVIIA) in congenital haemophilia with inhibitors by bleed type and location: the experience of the Haemophilia and Thrombosis Research Society (HTRS) Registry (2004-2008).

Authors:  G Young; D L Cooper; R Z Gut
Journal:  Haemophilia       Date:  2012-05-28       Impact factor: 4.287

Review 6.  Management of acute haemarthrosis in haemophilia A without inhibitors: literature review, European survey and recommendations.

Authors:  C Hermans; P De Moerloose; K Fischer; K Holstein; R Klamroth; T Lambert; G Lavigne-Lissalde; R Perez; M Richards; G Dolan
Journal:  Haemophilia       Date:  2011-02-15       Impact factor: 4.287

Review 7.  Genetic risk factors for inhibitors to factors VIII and IX.

Authors:  J Oldenburg; A Pavlova
Journal:  Haemophilia       Date:  2006-12       Impact factor: 4.287

8.  Immune tolerance in hemophilia-principal results from the International Registry. Report of the factor VIII and IX Subcommittee.

Authors:  G Mariani; A Ghirardini; R Bellocco
Journal:  Thromb Haemost       Date:  1994-07       Impact factor: 5.249

9.  Prophylactic treatment of haemophilia patients with inhibitors: clinical experience with recombinant factor VIIa in European Haemophilia Centres.

Authors:  M Morfini; G Auerswald; R A Kobelt; G F Rivolta; J Rodriguez-Martorell; F A Scaraggi; C Altisent; J Blatny; A Borel-Derlon; V Rossi
Journal:  Haemophilia       Date:  2007-09       Impact factor: 4.287

10.  The North American Immune Tolerance Registry: contributions to the thirty-year experience with immune tolerance therapy.

Authors:  D Dimichele
Journal:  Haemophilia       Date:  2008-10-30       Impact factor: 4.287
View more
  10 in total

Review 1.  Coagulation Factor IX (Recombinant), Albumin Fusion Protein (Albutrepenonacog Alfa; Idelvion®): A Review of Its Use in Haemophilia B.

Authors:  Katherine A Lyseng-Williamson
Journal:  Drugs       Date:  2017-01       Impact factor: 9.546

2.  Infused factor VIII-expressing platelets or megakaryocytes as a novel therapeutic strategy for hemophilia A.

Authors:  Randolph B Lyde; Hyun Sook Ahn; Karen K Vo; Danuta J Jarocha; John Tkaczynski; Elsa Treffeisen; Spencer K Sullivan; Rodney M Camire; Denise E Sabatino; Deborah L French; Mortimer Poncz
Journal:  Blood Adv       Date:  2019-05-14

3.  Assessing the Performance of Extended Half-Life Coagulation Factor VIII, FC Fusion Protein by Using Chromogenic and One-Stage Assays in Saudi Hemophilia A Patients.

Authors:  Tarek M Owaidah; Hazzaa A Alzahrani; Nouf S Al-Numair; Abdulmjeed O Alnosair; Amelita M Aguilos; Mahasen Saleh
Journal:  Adv Hematol       Date:  2020-09-09

Review 4.  The role of emicizumab, a bispecific factor IXa- and factor X-directed antibody, for the prevention of bleeding episodes in patients with hemophilia A.

Authors:  Tristan Knight; Michael U Callaghan
Journal:  Ther Adv Hematol       Date:  2018-10-10

5.  Expert opinion on the UK standard of care for haemophilia patients with inhibitors: a modified Delphi consensus study.

Authors:  Kate Khair; Elizabeth Chalmers; Thuvia Flannery; Annabel Griffiths; Felicity Rowley; Guillermo Tobaruela; Pratima Chowdary
Journal:  Ther Adv Hematol       Date:  2021-04-30

Review 6.  Innovative Approaches for Immune Tolerance to Factor VIII in the Treatment of Hemophilia A.

Authors:  Alexandra Sherman; Moanaro Biswas; Roland W Herzog
Journal:  Front Immunol       Date:  2017-11-24       Impact factor: 7.561

7.  The changing face of immune tolerance induction in haemophilia A with the advent of emicizumab.

Authors:  Manuel Carcao; Carmen Escuriola-Ettingshausen; Elena Santagostino; Johannes Oldenburg; Ri Liesner; Beatrice Nolan; Angelika Bátorová; Saturnino Haya; Guy Young
Journal:  Haemophilia       Date:  2019-04-29       Impact factor: 4.287

Review 8.  The Impact of Recombinant Versus Plasma-Derived Factor VIII Concentrates on Inhibitor Development in Previously Untreated Patients With Hemophilia A: A 2021 Update of a Systematic Review and Meta-Analysis.

Authors:  Kelvin Kohar; Stephanie A Prayogo; Lowilius Wiyono
Journal:  Cureus       Date:  2022-06-16

Review 9.  New developments in the management of moderate-to-severe hemophilia B.

Authors:  Moniba Nazeef; John P Sheehan
Journal:  J Blood Med       Date:  2016-04-01

10.  Two-incision laparoscopic appendectomy for a severe hemophilia A child patient with coagulation factor VII deficiency: Case report and review of literature.

Authors:  Jin Peng He; Jie Xiong Feng
Journal:  Medicine (Baltimore)       Date:  2017-10       Impact factor: 1.817
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.